Home  »  Trending   »  Aurinia Pharmaceuticals Inc. (AUPH) upgraded Issue...

Aurinia Pharmaceuticals Inc. (AUPH) upgraded Issued by Wall Street Gurus

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) went up by 4.66% from its latest closing price compared to the recent 1-year high of $33.97. The company’s stock price has collected 3.38% of gains in the last five trading sessions.

Is It Worth Investing in Aurinia Pharmaceuticals Inc. (NASDAQ :AUPH) Right Now?

Plus, the 36-month beta value for AUPH is at 0.97. Opinions of the stock are interesting as 7 analysts out of 8 who provided ratings for Aurinia Pharmaceuticals Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


AUPH currently public float of 132.67M and currently shorts hold a 9.45% ratio of that float. Today, the average trading volume of AUPH was 2.75M shares.

AUPH’s Market Performance

AUPH stocks went up by 3.38% for the week, with a monthly drop of -6.49% and a quarterly performance of -28.13%, while its annual performance rate touched -63.62%. The volatility ratio for the week stands at 5.31% while the volatility levels for the past 30 days are set at 5.88% for Aurinia Pharmaceuticals Inc. The simple moving average for the period of the last 20 days is 2.53% for AUPH stocks with a simple moving average of -41.05% for the last 200 days.

Analysts’ Opinion of AUPH

Many brokerage firms have already submitted their reports for AUPH stocks, with Cantor Fitzgerald repeating the rating for AUPH by listing it as a “Overweight.” The predicted price for AUPH in the upcoming period, according to Cantor Fitzgerald is $25 based on the research report published on May 05th of the current year 2022.

Oppenheimer, on the other hand, stated in their research note that they expect to see AUPH reach a price target of $31, previously predicting the price at $33. The rating they have provided for AUPH stocks is “Outperform” according to the report published on December 10th, 2021.

Oppenheimer gave a rating of “Perform” to AUPH, setting the target price at $32 in the report published on October 28th of the previous year.

AUPH Trading at -11.47% from the 50-Day Moving Average

After a stumble in the market that brought AUPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -77.51% of loss for the given period.

Volatility was left at 5.88%, however, over the last 30 days, the volatility rate increased by 5.31%, as shares sank -4.50% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -38.34% lower at present.

During the last 5 trading sessions, AUPH rose by +3.38%, which changed the moving average for the period of 200-days by -57.03% in comparison to the 20-day moving average, which settled at $7.43. In addition, Aurinia Pharmaceuticals Inc. saw -66.59% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at AUPH starting from MacKay-Dunn R. Hector, who purchase 5,000 shares at the price of $11.00 back on Mar 09. After this action, MacKay-Dunn R. Hector now owns 11,000 shares of Aurinia Pharmaceuticals Inc., valued at $54,985 using the latest closing price.

MILNE GEORGE M JR, the Director of Aurinia Pharmaceuticals Inc., purchase 5,000 shares at $10.82 during a trade that took place back on Mar 04, which means that MILNE GEORGE M JR is holding 50,000 shares at $54,100 based on the most recent closing price.

Stock Fundamentals for AUPH

Current profitability levels for the company are sitting at:

  • -395.05 for the present operating margin
  • +93.01 for the gross margin

The net margin for Aurinia Pharmaceuticals Inc. stands at -396.81. Equity return is now at value -38.00, with -33.10 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 12.63.

Is Cadence Bank (CADE) a Keeper?

Cadence Bank (NYSE:CADE) went down by -0.52% from its latest closing price compared to the recent 1-year high of $34.24. The company’s stock price has